Research dossier

IGF-1 LR3 — reduced IGFBP affinity dossier

An analogue engineered to escape its binding proteins — a deliberate structural modification.

7 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

IGF-1 LR3 — research dossier illustration

Molecular identity

ParameterValue
CAS number946870-92-4
Molar mass9117.5 g/mol
Molecular formulaC₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
Sequence / natureLong R3 IGF-1 (83-AA recombinant analog)
Purity≥99%
AppearanceWhite lyophilised powder

The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.

Research context

Engineering an analogue to escape its binding proteins is a conceptually interesting strategy: it treats sequestration as a modifiable parameter rather than a constraint. For a laboratory, the practical consequence is that the choice of culture medium becomes a major experimental decision.

Mechanism studied

IGF-1 LR3 is a recombinant analogue of insulin-like growth factor 1, carrying two modifications relative to the native human sequence: a substitution at position 3 (arginine replacing glutamic acid) and a 13-residue N-terminal extension.

The logic of those modifications is explicit in the literature: circulating IGF-1 is very largely sequestered by a family of binding proteins, the IGFBPs, which regulate its availability. The substitution at position 3 strongly reduces affinity for those proteins, which increases the free fraction available to the receptor.

That property has a direct methodological consequence in culture: serum-containing media supply IGFBPs, and the analogue is markedly less sequestered there than native IGF-1. Results obtained with one are therefore not transferable to the other without controlling the binding protein content.

The IGF-1R receptor is a receptor tyrosine kinase; its activation is measured by phosphorylation of the receptor and of the PI3K/Akt and MAPK pathways, detected by western blot.

In-vitro literature

The publications stress the need to control the composition of the medium. Assays in serum-free medium or in the presence of defined recombinant IGFBPs are the methodological standard.

Bibliographic entry points

These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.

Distinguishing this compound from its analogues

To be distinguished from native human IGF-1 and from the Des(1-3) variants. Affinities for the IGFBPs differ markedly between these forms.

The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.

Methodological limits

The binding protein composition of the medium is the decisive variable and the one most often neglected. An assay conducted in uncharacterised serum permits no quantitative comparison between publications. Being a recombinant protein, verification of folding — and not only of mass — governs activity.

These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.

Analytical parameters

A recombinant protein of more than 9 kDa, not a synthetic peptide. Folding and the disulfide bridges govern activity; the control methods differ from those applicable to short peptides.

ParameterValue
StorageStore at −20 °C, protected from light
SolubilitySoluble in bacteriostatic water (BAC)
StabilityStable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C
Control methodsRP-HPLC · MS · NMR

Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.

Resulting concentrations

The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.

Format1 ml2 ml3 ml
1mg1.00 mg/ml0.50 mg/ml0.33 mg/ml

These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.

Protocol design

Three points govern the validity of an assay using this material, whatever the question being asked.

The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.

The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.

The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.

Lot verification

The following formats are covered by a Janoshik Analytical report, readable from the product page:

  • 1mg — lot report available
FormatLot reportAvailability
1mgCoveredIn stock

The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.

Frequently asked questions

How does this product arrive?

As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.

Which solvent should be used for reconstitution?

Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.

How long does the material remain stable?

The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.

Does the analysis report correspond exactly to my vial?

The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.

Can this product be used on humans or animals?

No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.

Dossiers in the same category

Related dossiers

All research dossiers → · Catalogue → · Glossary →